Type 2 diabetes mellitus (T2DM) has become the third main chronic non-infectious disease following tumors and cardiovascular disease. Diagnosis of diabetes can help researchers efficiently analyze the causes of diabetes and advance the development of therapies. Ace Therapeutics can provide diagnostic development service of T2DM with more efficient function analysis.

Overview of T2DM Diagnosis

T2DM is associated with insulin resistance. The most important complications are heart disease, stroke, kidney failure (nephropathy), peripheral nerve damage and peripheral vascular disease. Classical diagnostic markers (blood glucose and HbA1C) are generally detected once metabolic imbalance has already set in. There is development of untargeted and targeted metabolomic techniques to examine the metabolite profiles of T2DM to find new diagnostic markers.

The Diagnosis of Diabetes (Petersmann, A.; et al. Experimental and Clinical Endocrinology & Diabetes. 2019)

T2DM Diagnostic Markers

The currently used therapies aim to delay progression of T2DM. There are a number of recognized biomarkers for type 2 diabetes mellitus risk, such as fasting plasma glucose and glycated hemoglobin A1c (HbA1c), triglycerides, adiponectin and inflammatory markers.

• Glucose-related Biomarkers
  The blood-based glucose-related testing includes hemoglobin Ale (HbAlc) (a product of non-enzymatic glycation), the fasting plasma glucose (FPG), and oral glucose tolerance test (OGTT).
• Blood Metabolites
  Some lipid metabolites (like triglycerides, cholesterol and lipoproteins), small molecule intermediates (2-hydroxybutyrate) and other metabolites (creatinine) help predict T2DM.
• Potential Biomarkers
  Some novel biomarkers like C-reactive protein, adipokines, incretins, cytokines, etc., in combination but not alone, for predicting T2DM. The untargeted and targeted metabolomic techniques can use to find some diagnostic markers (proteins, nucleic acids, and metabolites, etc.).

Impact of Hyperinsulinemia and T2DM on IFN-I Signaling (Veronica, V.; et al. Trends in Endocrinology & Metabolism. 2022)

Methods for T2DM Diagnosis

The routine diagnosis of T2DM is generally based on the plasma glucose values in a fasted state (FPG) and 2 hours after an oral intake of 75 g glucose (OGTT). Metabolomics is a potential tool for the discovery of new biomarkers in the early diagnosis of diseases. For example, the blood samples from type 2 diabetes mellitus model can employ chemistry analysis, 1D ¹H NMR and mass spectroscopy (FIA-MS/MS and LC-MS/MS) techniques to identify markers.

Our Services

The Effective diagnostics can help clients complete their disease model analysis more efficiently and better assessment of therapeutics and drug targets of T2DM. Ace Therapeutics can provide the T2DM diagnostic development services for different diagnostic markers (glucose, HbAlc, C-peptide, autoantibodies, proteins, nucleic acids, and metabolites, et al.).

In addition, we provide T2DM biomarker development and T2DM therapy development service for our clients worldwide.

Features of Our Services

Ace Therapeutics offers cost-effect and high-quality research services related to type 2 diabetes mellitus diagnostic development for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.

Reference

1. Petersmann, A.; et al. Definition, classification and diagnosis of diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes. 2019, 127(1), S1-S7.

• T2DM Pathological Research Service
• T2DM Therapy Development Service
• T2DM Modeling Service
• T2DM Biomarker Development Service

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators